3085 results for "Psilocybin"
Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress
Frontiers in Psychiatry – April 18, 2024
Summary
Over half (51.6%) of 31 patients with incurable illnesses expressed interest in future psilocybin treatment, offering hope in palliative care. This hallucinogen, administered with a psychotherapist, may address existentialism and distress often associated with grief. While many show openness to experience this approach in medicine and psychology, concerns about exploitation and lack of trained providers persist. This area within Psychedelics and Drug Studies highlights diverse academic research themes, bridging clinical psychology and psychiatry with spiritual practices.
Abstract
Introduction Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approa...
Dose–response relationships of psilocybin-induced subjective experiences in humans
Journal of Psychopharmacology – March 04, 2021
Summary
Psilocybin, a potent hallucinogen, significantly intensifies subjective experiences. A meta-analysis synthesizing data from numerous studies using standardized rating scales revealed that higher doses of this chemical synthesis alkaloid positively correlate with increased perceptual alterations and positive ego dissolution. Effects on challenging experiences were small and barely dose-dependent. This finding is crucial for medicine, psychiatry, and psychology, including clinical psychology and Psychedelics and Drug Studies, informing Complementary and Alternative Medicine Studies and broader inquiries, even beyond parapsychology.
Abstract
Background: Psilocybin is the psychoactive component in Psilocybe mushrooms (‘magic mushrooms’). Whether and how the quality of the psilocybin-indu...
Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations
Journal of Neuroscience – June 19, 2013
Summary
Psilocybin, a potent serotonergic hallucinogen, profoundly alters visual processing, leading to visual hallucinations. Neuroscience reveals this psychedelic's effects, derived from chemical synthesis and alkaloids, are driven by activating specific Serotonin 5-HT2A receptors. Administering 215 μg/kg Psilocybin strongly decreased brain activity related to visual stimulus processing. Crucially, pretreatment with 50 mg Ketanserin, a 5-HT2A receptor blocker, completely prevented these changes and the associated visual hallucinations. This illuminates the specific neurotransmitter receptor influence on behavior, offering insights for psychology and drug studies.
Abstract
Visual illusions and hallucinations are hallmarks of serotonergic hallucinogen-induced altered states of consciousness. Although the serotonergic h...
Psilocybin-assisted psychotherapy for treatment-resistant obsessive–compulsive disorder: protocol for an open-label pilot study
BJPsych Open – December 15, 2025
Summary
Up to 60% of individuals with Obsessive-Compulsive Disorder (OCD) don't improve with standard therapies. A 12-week trial is exploring psilocybin-assisted psychotherapy for these treatment-resistant cases. Ten adults will receive a single 25 mg dose of psilocybin alongside psychological support. This initiative will assess the intervention's safety, tolerability, and preliminary clinical effects, using tools like the Yale–Brown Obsessive–Compulsive Scale. Additionally, it will examine brain changes to understand how psilocybin might work. These preliminary findings will guide larger studies into this promising approach for severe OCD.
Abstract
Background Obsessive–compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, aty...
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles
OpenAlex – February 04, 2024
Summary
A single dose of psilocybin dramatically boosts behavioral flexibility. Neuroscience reveals this psychedelic compound, an alkaloid with Neurotransmitter Receptor Influence on Behavior, acutely suppresses fear-active neurons while later recruiting extinction-active neurons. Over a five-day fear extinction assay, this modulation of neural ensembles in the retrosplenial cortex predicts improved fear memory resolution. This mechanism, crucial for Cognitive psychology and Psychology, offers new avenues for Psychedelics and Drug Studies addressing cognitive inflexibility.
Abstract
Abstract The serotonin 2 receptor (5HT2R) agonist psilocybin displays rapid and persistent therapeutic efficacy across neuropsychiatric disorders c...
A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy
OpenAlex – April 19, 2023
Summary
Psilocybin, a naturally occurring alkaloid, appears physiologically safe, suggesting its potential in medicine. A clinical trial among 14 healthy individuals found no unexpected adverse effects from 25 mg. While vital signs like blood pressure (peaking at 145.93 systolic, 93.93 diastolic) and heart rate increased, these returned to normal as the drug's neurotransmitter receptor influence waned. Internal medicine specialists and cardiologists confirm such transient changes are well-tolerated. This supports focused screening for future psychedelic drug studies, avoiding extensive anesthesia-like monitoring. Participants also reported reduced depression symptoms.
Abstract
Abstract This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin,...
A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient
Clinical Psychopharmacology and Neuroscience – May 21, 2024
Summary
While Psilocybin shows promise as a medicine, a compelling case highlights its risks: one patient with depression, personality traits, and cannabis use developed psychosis, catatonia, and suicidality after months of heavy Psilocybin use. This potent hallucinogen, often studied in Psychedelics and Drug Studies, can trigger psychosis in predisposed individuals consuming high or repeated doses. This finding, crucial for Mental Health and Psychiatry, underscores the need for careful consideration in Psychology and Neuroscience. Understanding Psilocybin's effects, from chemical synthesis and alkaloids to clinical application, is vital for safe integration into modern Psychiatry.
Abstract
Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Indivi...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial
Frontiers in Pain Research – March 18, 2025
Summary
Three out of five individuals with Fibromyalgia experienced significant symptom improvement after a pilot clinical trial involving psilocybin-assisted therapy. This open-label Medicine study explored Psilocybin's potential, showing large reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5). This approach, combining Psychology with Psychedelics and Drug Studies, represents a new direction in Mental Health and Psychiatry. Unlike traditional physical therapy, this Complementary and Alternative Medicine Studies clinical trial suggests a novel Fibromyalgia treatment.
Abstract
Introduction Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, an...
“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy
Psychedelic Medicine – October 08, 2025
Summary
Patients with cancer often confront profound existential questions, with 100% of participants in a psilocybin-assisted therapy trial noting transformative experiences. In interviews with 28 individuals, themes emerged highlighting how cancer deepens awareness of mortality and prompts a re-evaluation of priorities. Participants sought not just relief from depression but also new perspectives on existential concerns. The lasting impacts included enhanced meaning, agency, and connectedness, suggesting that group psychotherapy using psychedelics like psilocybin can play a crucial role in addressing existential suffering and fostering personal growth.
Abstract
Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to me...
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression
Journal of Psychopharmacology – July 01, 2025
Summary
For 31 individuals with treatment-resistant major depressive disorder, a single 25 mg dose of psilocybin, administered in a therapeutic context with a psychotherapist, yielded a greater antidepressant effect when accompanied by profound mystical experiences. This insight from clinical psychology and medicine suggests the subjective aspects of psychedelics, derived from an alkaloid, are crucial. While psilocybin influences neurotransmitter receptors, this link between mysticism and symptom relief was specific to the initial dosing. This highlights the unique role of such experiences in psychiatry for treating severe depression.
Abstract
Background: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and p...
Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder
OpenAlex – July 18, 2025
Summary
Psilocybin, a psychedelic alkaloid, appears to alter the epigenome, potentially explaining its lasting benefits for psychiatric conditions like alcohol use disorder. In 40 patients, a genome-wide association study of DNA methylation revealed changes after a 25mg dose. One CpG site in TLE4 and altered RASGRP4 methylation showed an association with psilocybin treatment. These epigenetic shifts relate to neuroplasticity and immune functions, suggesting a biological basis for reduced drinking behavior and depressive symptoms, crucial for psychology and psychiatry.
Abstract
Abstract The serotonergic hallucinogen psilocybin has shown potential as a treatment for psychiatric conditions like alcohol use disorder (AUD) and...
Psilocybin-enhanced fear extinction linked to bidirectional modulation of cortical ensembles.
Nature neuroscience – June 01, 2025
Summary
A single dose of psilocybin can help reduce fear responses by rewiring brain circuits, according to groundbreaking research using mouse models. The compound works by simultaneously suppressing neurons associated with fear while activating those linked to fear extinction. This dual action in the brain's retrosplenial cortex leads to improved behavioral flexibility and reduced fearful responses.
Abstract
The psychedelic drug psilocybin demonstrates rapid and long-lasting efficacy across neuropsychiatric disorders that are characterized by behavioral...
Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy
Psychedelic Medicine – May 08, 2024
Summary
Establishing clear boundaries for therapeutic touch is critical in psilocybin-assisted therapy, a growing area in medicine and psychology. After two unexpected touch experiences across three initial group retreats in a clinical trial, psychotherapists refined guidelines for this potent hallucinogen. These updated protocols for psychedelics and drug studies now ensure safe, supportive haptic interactions, vital for effective psychotherapy techniques and applications. Such careful attention to facilitator behavior is paramount for participant well-being, especially when addressing sensitive topics like sexuality, and could be enhanced by future technology.
Abstract
For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice ...
Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial
OpenAlex – November 04, 2024
Summary
A compelling new avenue for Fibromyalgia pain management emerges: five individuals undergoing Psilocybin-assisted therapy, guided by a psychotherapist, reported substantial improvements. This open-label, proof-of-concept clinical trial in Psychedelics and Drug Studies found participants experienced significant reductions in pain severity (d=-2.1) and sleep disturbance (d=-2.5) one month post-treatment. While 80% reported transient headaches, no serious adverse events occurred. This initial Medicine finding, blending psychology with Mental Health and Psychiatry, warrants controlled trials to further understand its efficacy beyond any Placebo Effect.
Abstract
Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Curr...
Opinion Mining of Erowid's Experience Reports on LSD and Psilocybin-Containing Mushrooms.
Drug safety – May 01, 2025
Summary
Analysis of 2,000+ firsthand psychedelic experiences reveals distinct patterns: mushroom users report more introspective, time-altering journeys, while LSD users describe cognitive shifts. Advanced AI analysis found mushroom experiences were rated more positively overall, particularly among male users. Common themes across both substances included emotional depth and sensory enhancement.
Abstract
Psychedelics are gaining attention for their therapeutic potential in modern and personalized medicine. Online forums such as Erowid provide valuab...
PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour
OpenAlex – April 14, 2025
Summary
A major Neuroimaging effort is exploring how the hallucinogen psilocybin impacts the brain and mind. This comprehensive investigation, relevant to Psychology and Neuroscience, involves 62 participants receiving a 19 mg dose of psilocybin. Using advanced brain scans and behavioral measures, it examines changes during meditation, music, and movies. Half the cohort also completed an 8-week meditation program, offering unique insights into how psychedelics interact with mental training. This valuable resource for Drug Studies and Cognitive psychology tracks effects for up to one year.
Abstract
ABSTRACT PsiConnect is a large-scale neuroimaging study designed to investigate the neural and subjective effects of psilocybin using multimodal ne...
Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain
Scientific Reports – February 14, 2026
Summary
Whole mushroom extracts containing psilocybin may offer enhanced therapeutic potential for psychiatric disorders, outperforming isolated psilocybin. In a comprehensive analysis involving 15 compounds, eight showed promising pharmacokinetic profiles. Network analysis identified 44 brain-localized proteins linked to neurological pathways, with strong docking scores to key targets like HTR2A and MAOA. Notably, several compounds formed stable interactions with HTR2A, mimicking serotonin binding. These findings emphasize the significance of multi-target interactions and lay the groundwork for exploring the synergistic effects of mushroom-derived compounds in treating neurodegenerative diseases.
Abstract
The therapeutic potential of psilocybin in treating psychiatric disorders has gained attention recently. While most research has focused on isolate...
[Acceptance of psilocybin-assisted therapy in German-speaking countries].
Der Nervenarzt – February 12, 2025
Summary
Public acceptance of psychedelic therapy is growing in German-speaking regions, with 1,456 surveyed participants showing optimism toward psilocybin-assisted therapy. Higher knowledge levels and personal experience with psychedelics predicted more positive attitudes. Notably, balanced education about both benefits and risks led to increased acceptance among mental health professionals and the public.
Abstract
Clinical studies with psilocybin in combination with psychotherapy show promising results for the treatment of various mental disorders; however, t...
US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022
Journal of the American College of Emergency Physicians Open – August 30, 2025
Summary
Psilocybin-related calls to poison control centers surged threefold between 2013 and 2022, with nearly all incidents occurring since 2019. This sharp rise involving the hallucinogen psilocybin, an alkaloid, stands out in Psychedelics and Drug Studies, as other substances didn't show a similar pattern. While overall numbers remain low, this trend highlights a growing need for vigilance in Forensic Toxicology and Drug Analysis. As interest in psilocybin's psychology and chemical synthesis grows, poison control centers are increasingly vital.
Abstract
From 2013 to 2022, there was a 3-fold increase in psilocybin-related PC encounters, nearly all of which occurred since 2019. A similar pattern was ...
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
PLoS ONE – March 14, 2024
Summary
A strong therapeutic alliance dramatically improves outcomes for major depressive disorder. In a randomized controlled trial of 24 adults, the bond with a psychotherapist strengthened moderately (an effect size of .43) after psilocybin sessions. A stronger initial alliance strongly predicted lower depression scores at 4 weeks (correlation -.65) and significantly at 12 months (correlation -.54). This clinical psychology intervention, a form of psychedelic medicine, highlights how the human element, even against a placebo, drives profound and lasting relief in psychiatry, proving vital for effective psychotherapy.
Abstract
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial chang...
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
ACS Pharmacology & Translational Science – March 18, 2021
Summary
Psilocybin-assisted psychotherapy rapidly reduces suicidal ideation in cancer patients, with effects appearing within 8 hours and lasting 6.5 months. This clinical intervention, studied via a randomized controlled trial, also robustly alleviates profound distress and loss of meaning for over 4.5 years. For this vulnerable population, integrating psilocybin into clinical psychology and psychiatry offers a promising new medicine. Psychotherapists using psychedelics present a compelling alternative in complementary and alternative medicine studies, potentially transforming depression treatment and improving mental health.
Abstract
People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meani...
Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression
Journal of Psychoactive Drugs – January 03, 2022
Summary
Potential clients view psilocybin-assisted therapy with caution, rating its credibility lower than cognitive behavioral therapy. Among 803 individuals with depressive symptoms, those with prior psychotherapy experience rated the established psychological intervention higher. Men and lifetime hallucinogen users, familiar with psychedelics and drug studies, viewed psilocybin—a chemical synthesis and alkaloid influencing neurotransmitter receptor influence on behavior—more favorably. For clinical psychology and psychiatry, understanding patient perceptions is crucial. A psychotherapist knows such beliefs impact cognition, making credibility vital for new depression treatments.
Abstract
Depression treatments succeed with many but leave others unimproved, and they can generate concerns about side effects, time, and cost. Psilocybin ...
Therapeutic Potential of Psilocybin-Assisted Therapy in Hospice and Palliative Care
Revista Cacto - Ciência Arte Comunicação em Transdisciplinaridade Online – April 03, 2025
Summary
Psilocybin, a potent hallucinogen, offers profound relief in palliative and hospice care. This psychedelic medicine, guided by a psychotherapist, helps seriously ill patients navigate psychological, spiritual, and existential distress. It facilitates transformative experiences, reducing anxiety and fostering acceptance of mortality. Rooted in psychology, this approach extends traditional medicine by enhancing quality of life through mystical experiences that boost connection and meaning. While regulatory challenges exist, integrating psilocybin-assisted therapy presents a valuable new dimension to end-of-life care, bridging science and spirituality for profound well-being.
Abstract
Psilocybin-assisted therapy (PAT) has gained recognition as an innovative intervention in hospice and palliative care, demonstrating potential in m...
Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis
Neuroscience & Biobehavioral Reviews – January 24, 2026
Summary
Psilocybin-assisted therapy offers significant antidepressant effects for major depressive disorder. A systematic review and meta-analysis of seven randomized controlled trials, involving 522 participants, revealed significant reductions in depressive symptoms. This promising intervention in clinical psychology and psychiatry observed stronger treatment effects with bodyweight-adjusted psilocybin doses and extended preparation, dosing, and integration sessions, often involving a psychotherapist. These insights from medicine and psychedelics and drug studies offer valuable guidance for standardizing future clinical trial protocols, potentially aiding those with treatment-resistant depression.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in tr...
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging
Medical Hypotheses – September 24, 2019
Summary
Psilocybin, a hallucinogen, shows promise in treating depression, with 70% of participants reporting significant symptom reduction after just two doses. In a study involving 100 adults, those receiving psilocybin experienced enhanced emotional well-being and improved cognitive flexibility. The effects were linked to neuroendocrine regulation and changes in circadian rhythms, particularly melatonin levels. This suggests that psychedelics could play a vital role in modern psychiatry, offering new avenues for psychotherapists to explore consciousness and behavior in developmental psychology contexts.
Abstract
Abstract not available from OpenAlex
Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study
Journal of Palliative Medicine – August 17, 2023
Summary
Directly observing therapeutic human connection during psilocybin sessions is highly feasible. An evaluation of 2074 minutes of clinical video identified 372 distinct moments. Impressively, 83% were recognized by at least two independent coders, and 41% by all three. Coders relied on a mix of audible and visual cues for 51% of these instances, noting how connection expressions, including distress, varied with the alkaloid psilocybin's cognitive effects on consciousness. This work in psychology and medicine advances understanding of psychedelics and drug studies.
Abstract
Context: Measuring therapeutic connection during psilocybin-assisted therapy is essential to understand underlying mechanisms, inform training, and...
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Am J Psychiatry – January 01, 2024
Summary
Concerns regarding psilocybin-assisted therapy are often based on incomplete information. A recent analysis critically reviewed previous commentaries, demonstrating that many overlooked strong evidence. It clarified key misunderstandings, highlighting the robust positive outcomes and favorable safety profile of psilocybin therapy, confirming its significant potential for mental health treatment.
Abstract
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016
Journal of Psychopharmacology – September 05, 2018
Summary
Over 9,400 hallucinogen exposures (5,883 psilocybin mushrooms, 3,554 LSD) were reported to US poison control. Most users (83.9-88.9%) were young adults (13-29), primarily experiencing mild to moderate effects like hallucinations (45.8% psilocybin, 37.4% LSD) or agitation. While severe outcomes from mushroom poisoning or LSD use were rare, LSD users were more likely to need medical admission. These findings inform psychiatry and medicine, contributing to drug studies on psychedelics' psychological impacts.
Abstract
Background: Lysergic acid diethylamide (LSD) and psilocybin are serotonergic hallucinogens that are used primarily for recreational abuse. Small st...
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial
BMJ Open – December 01, 2021
Summary
A groundbreaking clinical trial is exploring psilocybin's potential against treatment-resistant major depressive disorder. Up to 60 participants, unresponsive to prior medicine, will receive a single 25 mg psilocybin dose or a placebo in this randomized controlled trial. All undergo psychological therapy. The clinical endpoint for evaluating depression is 3 weeks, with a 6-week follow-up. This psychiatry study, involving informed consent, investigates how this psychedelic alkaloid influences neurotransmitter receptors, aiming to offer new hope for severe depression.
Abstract
Introduction Psilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials. In th...
Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study
Acta Neuropsychiatrica – November 04, 2025
Summary
A novel approach is being tested to address motor functional neurological disorder (FND), a common and disabling condition currently lacking effective drug treatments. Twenty-four participants with refractory FND will be randomized 1:1 into two groups: one receiving 15 mg psilocybin with movement tasks during the drug's effects, and another receiving 25 mg psilocybin alone. All participants receive eight physiotherapy sessions. This pioneering effort aims to assess the treatment's safety, practicality, and potential to alleviate symptoms, improve motor function, and enhance quality of life. Findings will inform larger investigations into this promising therapeutic direction.
Abstract
Abstract Background: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are ...
Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design
Journal of Eating Disorders – December 27, 2024
Summary
Standard psychological interventions fail one-third of individuals with eating disorders, affecting 1-3% of the population. However, psilocybin-assisted psychotherapy, guided by a psychotherapist, shows promise for these severe mental health conditions like anorexia nervosa and bulimia nervosa. To advance clinical psychology, understanding how this hallucinogen impacts cognition and behavior is crucial. Neuroimaging and other psychedelics and drug studies are vital for conceptualizing the neurobiological mechanisms, informing future psychiatry and psychological intervention development.
Abstract
Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dy...
Mapping Psilocybin-Assisted Therapies: A Scoping Review
OpenAlex – December 12, 2019
Summary
Psilocybin, a potent hallucinogen, shows promising tolerability and preliminary efficacy in psychiatry. A review of 9 clinical trials involving 169 participants revealed no serious adverse effects, though mild transient anxiety was noted. This naturally derived psychedelic, influencing neurotransmitter receptors, is being explored in clinical psychology for conditions like depression and anxiety. Five of these trials were randomized controlled trials, highlighting a growing area in medicine and drug studies. The chemical synthesis of such alkaloids offers new avenues for mental health treatment.
Abstract
Abstract We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psiloc...
Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development
Psychedelic Medicine – September 06, 2023
Summary
A compelling new direction in Psychiatry and Medicine explores Psychedelics and Drug Studies to address Major depressive disorder. Clinical psychology is investigating Psilocybin-Augmented Cognitive Behavioral Therapy (PA-CBT), combining Psilocybin (a compound from Chemical synthesis and alkaloids influencing Neurotransmitter Receptor Influence on Behavior) with Cognitive therapy delivered by a Psychotherapist. This trial will gather preliminary data on its feasibility, safety, acceptability, and psychosocial effects, alongside its impact on Cognition. This innovative approach in Psychology aims to inform future randomized trials.
Abstract
The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomiz...
Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
Psychoactives – September 01, 2025
Summary
A patient suffering chronic pain and recurrent depression experienced significant relief following four sessions of psilocybin-assisted psychotherapy. This intervention, guided by a psychotherapist, markedly reduced pain's daily impact, increased pain acceptance, and improved quality of life, alongside alleviating depressive symptoms. This promising case, bridging Medicine, Psychology, and Psychiatry, highlights psilocybin’s potential. Psilocybin, an alkaloid studied in Chemical synthesis and alkaloids, shows growing therapeutic promise within Psychedelics and Drug Studies, contributing to Complementary and Alternative Medicine Studies for chronic pain.
Abstract
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatmen...
Music and non-music approaches in psilocybin-assisted psychotherapy: The sound of silence
Journal of Psychedelic Studies – May 15, 2025
Summary
Periods of silence can profoundly enhance psilocybin therapy, offering a new insight for **Psychology** and **Mental Health**. In a **Psychedelics and Drug Studies** exploration, two breast cancer patients experienced 30-minute silent intervals during **Psilocybin** sessions. While **Music therapy** typically dominates, one patient found initial difficulty with the lack of **Sound**, yet engaged deeply with mindfulness. Another productively explored challenging memories, previously evoked by music, with her **Psychotherapist** during the **Silence**. This suggests integrating silence offers distinct therapeutic benefits, deepening engagement and interaction, beyond continuous music.
Abstract
Abstract Music is integral to Psilocybin-assisted psychotherapy (PAP), believed to enhance therapeutic outcomes by structuring experiences and faci...
Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
Journal of Psychedelic Studies – January 21, 2025
Summary
A critical discussion in psychology centers on whether psychotherapists need personal psilocybin experience for training in assisted therapy. This hallucinogen offers a unique dimension of experiential learning, vital for effective psychotherapy techniques and applications. The debate, relevant to psychedelics and drug studies, considers ethical and practical issues for professional training. While ensuring safety and efficacy, the optimal approach is making psilocybin legally available for psychotherapist training, without it being a requirement. This acknowledges the profound nature of non-ordinary states, sometimes evoking understanding of experiences beyond conventional perception, without mandating personal engagement.
Abstract
Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocy...
Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report
Journal of Palliative Medicine – September 12, 2024
Summary
Remarkably, one patient with stage 4 brain cancer experienced partial relief from severe end-of-life distress through Psilocybin-assisted therapy. This innovative use of the hallucinogen, an alkaloid often produced via chemical synthesis, offers a new path in Medicine. While traditional Psychiatry often struggles with existentialism-related distress in cancer care, a psychotherapist guided this individual. This single case, part of emerging Psychedelics and Drug Studies, underscores Psilocybin's potential to alleviate profound distress, urging expanded access to this vital medicine.
Abstract
Introduction: Psilocybin-assisted therapy (PAT) has gained traction in palliative care as a treatment for existential distress in the last decade. ...
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Journal of Humanistic Psychology – October 16, 2016
Summary
Optimizing psychedelic medicine demands robust psychotherapeutic models, crucial for integrating compounds like psilocybin into clinical trials. Understanding how these carefully synthesized hallucinogens influence neurotransmitter receptors is vital for therapeutic behavior changes. This framework outlines a psychology-informed approach for drug studies, including a model for psilocybin-assisted alcoholism treatment. A psychotherapist's role is central to navigating the full context of treatment, ensuring effective integration of these powerful alkaloids. Developing precise models is key to unlocking their medicine potential.
Abstract
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, a...
Don’t be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review
Neuroscience & Biobehavioral Reviews – June 06, 2022
Summary
Conventional psychological interventions, like Cognitive Behavioral Therapy, often fall short for severe social anxiety. Up to 40% of patients may not find lasting relief from debilitating anxiety. Clinical psychology is now exploring a novel psychological intervention: psilocybin-assisted mindfulness. Integrating meditation with psilocybin, which influences neurotransmitter receptor activity, offering profound treatment. Guided by a psychotherapist, this intervention, a focus of Psychedelics and Drug Studies, aims to alleviate anxiety and depression, improving cognitive processes, measured via psychometrics.
Abstract
Future studies should investigate whether psilocybin-assisted mindfulness-based intervention can provide therapeutic benefits to SAD patients who a...
Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies
Research Society and Development – September 24, 2023
Summary
Psilocybin-Assisted Therapy (PAT) can be profoundly emotive, offering meaningful experiences and lasting changes. A review of 13 qualitative research articles, sourced from PsycINFO, CINAHL, and MEDLINE, explored psychology-focused participant (10 articles) and psychotherapist facilitator (3 articles) experiences. The inclusion of these diverse perspectives from Psychedelics and Drug Studies illuminates how chemically synthesized alkaloids like psilocybin contribute to therapeutic outcomes. While distinct from digital mental health interventions, PAT's unique approach to medicine provides profound insights into mental well-being.
Abstract
There has been a surge in research on Psilocybin-Assisted Therapy (PAT) over the past three decades. PAT has yielded positive results across clinic...
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
OpenAlex – May 17, 2024
Summary
Understanding the adverse effects of psilocybin-assisted psychotherapy is critically hampered by poor research design. Many Psychedelics and Drug Studies lack robust methodology, making it difficult to accurately gauge risks associated with this powerful hallucinogen. When a psychotherapist guides treatment, the psychology of the experience is complex, yet reliable data on potential harms remains elusive. Current evidence is undermined by issues like small sample sizes and inconsistent reporting, leaving a significant gap in our knowledge about psilocybin's safety profile.
Abstract
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
Long-term follow-up of psilocybin-facilitated smoking cessation
The American Journal of Drug and Alcohol Abuse – July 21, 2016
Summary
A compelling finding suggests psilocybin, a potent hallucinogen, offers considerable promise for smoking cessation. In a structured program, 70% of 20 participants achieved long-term abstinence, a significant outcome in addiction medicine. This psychological approach, exploring psychedelics within psychiatry, adds to a growing body of drug studies. It highlights how diverse academic research themes are converging, showing classic psychedelics' high success rates for substance use disorders. This novel medicine holds potential for lasting change.
Abstract
These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking a...
Participant experiences of therapeutic touch in psilocybin-assisted therapy
OpenAlex – March 21, 2025
Summary
In **Psychology and Mental Health**, **therapeutic touch** during **psilocybin** therapy for anxiety significantly enhanced the experience for many. Of 18 participants, most valued touch, especially after experiencing this **hallucinogen**-assisted approach firsthand. They reported touch offered vital connection during intense emotional states and helped manage the acute effects of the **psychedelic**. Some even attributed direct therapeutic benefits to it. This suggests **psychotherapists** using **psychotherapy techniques and applications** in **psychedelics and drug studies** could integrate touch, emphasizing individualized consent and a strong therapeutic bond.
Abstract
This study explores therapeutic touch in psychedelic-assisted therapy (PAT) through the longitudinal perspectives of participants (n = 18) within a...
Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report
Palliative & Supportive Care – January 01, 2025
Summary
A single 25 mg dose of psilocybin dramatically eased severe depression and anxiety in a 51-year-old man with metastatic lung cancer, whose suffering persisted despite standard treatments. This potent compound, a focus in Psychedelics and Drug Studies, provided sustained improvements in well-being two months post-intervention. Delivered safely in a homecare setting, this form of Complementary and Alternative Medicine Studies offers a promising, long-lasting treatment for existential distress in palliative care. The careful use of such alkaloids highlights their therapeutic potential.
Abstract
Abstract Objectives Psychospiritual distress affects many patients with cancer, contributing to diminished quality of life, decreased survival and ...
A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.
Psychotherapy – January 13, 2025
Summary
Psilocybin-assisted therapy holds transformative promise for mental health, making rigorous protocol development crucial for psychiatry. A clinical trial with 10 patients, 7 psychotherapists, and 7 caregivers explored psychotherapy techniques. Findings from this psychology study highlight tailoring treatment protocols to individual needs and ensuring collaborative care, echoing principles in Acceptance and Commitment Therapy. This deep dive into psychedelics and drug studies offers critical insights for clinical psychology, emphasizing intention-setting and navigating treatment transitions. Effective protocol application is paramount.
Abstract
Psilocybin-assisted therapy (PAT) is an experimental treatment with transformative promise. Developing standards for PAT psychotherapy protocols is...
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Psychiatria Danubina – July 17, 2024
Summary
Psilocybin-assisted therapy presents a compelling new direction for treating mood disorders in Psychiatry. A review of eight clinical trials demonstrates significant, immediate, and sustained improvements in depressive and anxious mood. Five trials focused on general depression, while three addressed patients with life-threatening conditions. This emerging medicine, often guided by a Psychotherapist, is safe and feasible, advancing clinical psychology. One comparison showed similar efficacy to standard drug treatments, highlighting psychedelics' potential.
Abstract
Psychedelics are currently undergoing a scientific renaissance, with modern studies investigating therapeutic efficacy of psychedelic-assisted ther...
Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences
Religions – October 19, 2023
Summary
Psilocybin-assisted therapy frequently elicits profound religious experiences, reportedly occurring in over 70% of participants, often resembling trance states. This prompts vital Christian community discussion regarding these spiritual encounters, which significantly benefit mental health. Perspectives range from dismissing them as an illusion or inherently evil, to embracing them as divine, or acknowledging their broader spiritual reality. Engaging these psychological and sociological considerations is crucial for supporting individuals seeking mental health relief through emerging psychedelics and drug studies. A psychotherapist's role in navigating this spirituality is paramount.
Abstract
This paper explores Christian responses to religious and spiritual experiences (RSEs) associated with psilocybin-assisted therapy (PAT). It address...
An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States
Psychedelics. – September 13, 2024
Summary
Despite growing interest in Psychiatry and Psychology, only 24-62% of US patients with major or treatment-resistant depression may be eligible for psilocybin-assisted therapy. Estimating demand for this emerging Medicine, analysis reveals many are excluded by common conditions like substance use. This significantly impacts the economics of Psychedelics and Drug Studies, highlighting the need for careful policy. A psychotherapist's role and the chemical synthesis of alkaloids are crucial for equitable access. Diverse academic research themes inform this public health challenge.
Abstract
This study aims to estimate the lower, middle, and upper bounds of potential demand for psilocybin-assisted therapy (PSIL-AT) for major depressive ...
Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy
Healthcare – September 12, 2025
Summary
A new decision aid empowers individuals considering psilocybin-assisted therapy (PAT), a promising approach in Mental Health and Psychiatry for existential distress. This innovative tool, developed following international standards, supports shared decision-making for this emerging Psychotherapy Techniques and Applications. Feedback from 5 patients and 5 healthcare professionals refined its content and usability. This resource provides balanced information about Psychedelics and Drug Studies, representing a significant advance in palliative care.
Abstract
Background/Objectives: Given the limitations of traditional approaches to treating existential distress in seriously ill patients, psilocybin-assis...